Plus Therapeutics Inc./$PSTV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Plus Therapeutics Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Ticker
$PSTV
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
21
ISIN
US72941H5090
Website
PSTV Metrics
BasicAdvanced
$18M
-
-$3.50
0.69
-
Price and volume
Market cap
$18M
Beta
0.69
52-week high
$2.31
52-week low
$0.16
Average daily volume
50M
Financial strength
Current ratio
1.029
Quick ratio
0.934
Total debt to equity
-0.169
Interest coverage (TTM)
-21.55%
Profitability
EBITDA (TTM)
-14.218
Gross margin (TTM)
-83.88%
Net profit margin (TTM)
-520.90%
Operating margin (TTM)
-286.82%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
-105.59%
Return on equity (TTM)
190.45%
Valuation
Price to revenue (TTM)
0.62
Price to book
-0.25
Price to tangible book (TTM)
-0.24
Price to free cash flow (TTM)
-0.251
Free cash flow yield (TTM)
-398.41%
Free cash flow per share (TTM)
-139.84%
Growth
Revenue change (TTM)
-14.43%
Earnings per share change (TTM)
8.09%
10-year revenue growth (CAGR)
-4.80%
3-year earnings per share growth (CAGR)
-37.65%
PSTV News
AllArticlesVideos
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference
GlobeNewsWire·2 days ago
Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
GlobeNewsWire·4 days ago
Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Plus Therapeutics Inc. stock?
Plus Therapeutics Inc. (PSTV) has a market cap of $18M as of July 11, 2025.
What is the P/E ratio for Plus Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Plus Therapeutics Inc. (PSTV) stock is 0 as of July 11, 2025.
Does Plus Therapeutics Inc. stock pay dividends?
No, Plus Therapeutics Inc. (PSTV) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Plus Therapeutics Inc. dividend payment date?
Plus Therapeutics Inc. (PSTV) stock does not pay dividends to its shareholders.
What is the beta indicator for Plus Therapeutics Inc.?
Plus Therapeutics Inc. (PSTV) has a beta rating of 0.69. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.